Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$25,153.09

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 51 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1659322691?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $25,153.09 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $127.3012/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135202638 CMS
Lilly USA, LLC $263.7012/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135263569 CMS
Lilly USA, LLC $800.0012/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247612 CMS
Lilly USA, LLC $11.6212/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217126 CMS
Lilly USA, LLC $1,000.0011/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135215494 CMS
Lilly USA, LLC $1,600.0011/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217867 CMS
Lilly USA, LLC $24.3911/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247608 CMS
Lilly USA, LLC $600.0011/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135174335 CMS
Lilly USA, LLC $40.2011/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135202646 CMS
Lilly USA, LLC $1,600.0011/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135215491 CMS
Lilly USA, LLC $15.5011/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217134 CMS
Lilly USA, LLC $800.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247625 CMS
Lilly USA, LLC $26.9410/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135215487 CMS
Lilly USA, LLC $20.0010/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247621 CMS
Lilly USA, LLC $20.0010/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135263574 CMS
Lilly USA, LLC $1,000.0010/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135174333 CMS
Lilly USA, LLC $1,600.0010/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135202642 CMS
Lilly USA, LLC $17.1310/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217130 CMS
Lilly USA, LLC $800.0010/03/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135254510 CMS
Lilly USA, LLC $15.1309/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135174331 CMS
Lilly USA, LLC $4,400.0009/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135247617 CMS
Lilly USA, LLC $683.3309/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217118 CMS
Lilly USA, LLC $15.9308/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135200693 CMS
Eisai Inc. $24.6608/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767539 CMS
Eisai Inc. $23.9706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767543 CMS
Eisai Inc. $23.2505/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767545 CMS
Otsuka America Pharmaceutical, Inc. $20.4305/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118864349 CMS
Lundbeck LLC $17.7805/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145898856 CMS
Eisai Inc. $20.5505/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767549 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $17.1005/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118835669 CMS
Otsuka America Pharmaceutical, Inc. $18.8704/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118864347 CMS
Lilly USA, LLC $13.7604/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135217122 CMS
E.R. Squibb & Sons, L.L.C. $666.4503/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101220590 CMS
E.R. Squibb & Sons, L.L.C. $308.0303/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101220592 CMS
E.R. Squibb & Sons, L.L.C. $328.3703/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101220596 CMS
Eisai Inc. $23.9903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767541 CMS
Eisai Inc. $1,755.0002/29/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767527 CMS
Eisai Inc. $124.9902/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767531 CMS
Eisai Inc. $1,462.5002/29/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767537 CMS
Eisai Inc. $1,213.6502/29/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155794118 CMS
Eisai Inc. $585.0002/27/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767553 CMS
Eisai Inc. $22.3002/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767551 CMS
Eisai Inc. $61.3402/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767529 CMS
Eisai Inc. $1,462.5002/20/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767533 CMS
Eisai Inc. $585.0002/20/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767535 CMS
Eisai Inc. $799.2402/20/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155794068 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $19.9802/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118835667 CMS
Otsuka America Pharmaceutical, Inc. $20.7402/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118864345 CMS
Lilly USA, LLC $13.7602/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135200691 CMS
Eisai Inc. $22.3601/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110767547 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

223 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $700.00 12/22/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213752234
Principal investigator 1 Novo Nordisk AS $6,910.74 12/22/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213806042
Principal investigator 1 Eisai Inc. $6,013.80 12/15/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557439
Principal investigator 1 Eisai Inc. $5,500.00 12/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557447
Principal investigator 1 Eisai Inc. $11,550.00 12/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557451
Principal investigator 1 Janssen Research & Development, LLC $500.00 12/01/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418901
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127237
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135856
Principal investigator 1 GlaxoSmithKline, LLC. $126.20 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135991
Principal investigator 1 GlaxoSmithKline, LLC. $301.86 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142540
Principal investigator 1 GlaxoSmithKline, LLC. $392.00 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146342
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 11/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184610
Principal investigator 1 GlaxoSmithKline, LLC. $11,157.76 11/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138273
Principal investigator 1 GlaxoSmithKline, LLC. $58.80 11/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127269
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 11/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129399
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 11/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135959
Principal investigator 1 GlaxoSmithKline, LLC. $107.18 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123165
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129405
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135893
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192136004
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145202
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145233
Principal investigator 1 GlaxoSmithKline, LLC. $130.81 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146346
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 11/04/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180942
Principal investigator 1 Eisai Inc. $15,200.00 11/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557445
Principal investigator 1 Eisai Inc. $11,340.00 11/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557449
Principal investigator 1 Eisai Inc. $3,870.00 11/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557453
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 10/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140726
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 10/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179635
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 10/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184639
Principal investigator 1 Eisai Inc. $250.00 10/21/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557435
Principal investigator 1 Eisai Inc. $22,770.90 10/20/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557437
Principal investigator 1 GlaxoSmithKline, LLC. $34,873.20 10/20/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146363
Principal investigator 1 GlaxoSmithKline, LLC. $57.12 10/20/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180962
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123173
Principal investigator 1 GlaxoSmithKline, LLC. $57.21 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123192
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127229
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127284
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135951
Principal investigator 1 GlaxoSmithKline, LLC. $62.37 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135997
Principal investigator 1 GlaxoSmithKline, LLC. $56.79 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140714
Principal investigator 1 GlaxoSmithKline, LLC. $358.40 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140720
Principal investigator 1 GlaxoSmithKline, LLC. $57.12 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140731
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140735
Principal investigator 1 GlaxoSmithKline, LLC. $610.40 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142502
Principal investigator 1 GlaxoSmithKline, LLC. $311.50 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142528
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148488
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180958
Principal investigator 1 GlaxoSmithKline, LLC. $179.20 10/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184621
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127261
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135864
Principal investigator 1 GlaxoSmithKline, LLC. $58.80 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135979
Principal investigator 1 GlaxoSmithKline, LLC. $607.50 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138267
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146355
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 10/16/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148511
Principal investigator 1 Eisai Inc. $7,600.00 10/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557441
Principal investigator 1 Eisai Inc. $7,750.00 10/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557443
Principal investigator 1 Eisai Inc. $16,375.00 10/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557455
Principal investigator 1 Novo Nordisk AS $779.76 09/19/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214102707
Principal investigator 1 Eisai Inc. $13,199.40 09/15/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557433
Principal investigator 1 Janssen Research & Development, LLC $7,704.00 09/15/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418881
Principal investigator 1 Janssen Research & Development, LLC $6,626.00 09/15/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418950
Principal investigator 1 GlaxoSmithKline, LLC. $16,935.75 09/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129412
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145210
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 09/12/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145225
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135897
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 09/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145229
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 09/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148481
Principal investigator 1 Biogen, Inc. $14,730.03 09/03/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1236946856
Principal investigator 1 Eisai Inc. $7,120.00 09/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557465
Principal investigator 1 Eisai Inc. $3,870.00 09/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557487
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 09/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127255
Principal investigator 1 GlaxoSmithKline, LLC. $120.00 09/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129370
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 09/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179631
Principal investigator 1 ABBVIE INC. $2,600.00 08/27/2025 Non-covered Recipient Entity
AMC RESEARCH LLC
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease No dispute reported 06/30/2026 1202505969
Principal investigator 1 GlaxoSmithKline, LLC. $57.12 08/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123205
Principal investigator 1 GlaxoSmithKline, LLC. $103.73 08/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184614
Principal investigator 1 Novo Nordisk AS $6,964.74 08/22/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214103579
Principal investigator 1 GlaxoSmithKline, LLC. $12,973.50 08/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142515
Principal investigator 1 Eisai Inc. $10,642.50 08/11/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557431
Principal investigator 1 Janssen Research & Development, LLC $500.00 08/11/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418985
Principal investigator 1 Janssen Research & Development, LLC $1,720.00 08/08/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418876
Principal investigator 1 Janssen Research & Development, LLC $38,790.00 08/08/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418887
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 08/08/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418913
Principal investigator 1 GlaxoSmithKline, LLC. $229.92 08/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123187
Principal investigator 1 GlaxoSmithKline, LLC. $103.03 08/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135877
Principal investigator 1 GlaxoSmithKline, LLC. $86.44 08/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148493
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 08/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140742
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 08/05/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142508
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 07/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127243
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 07/29/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135871
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,786.09 07/28/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235999059
Principal investigator 1 Janssen Research & Development, LLC $19,916.00 07/25/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419011
Principal investigator 1 Janssen Research & Development, LLC $1,680.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418830
Principal investigator 1 Janssen Research & Development, LLC $7,119.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418841
Principal investigator 1 Janssen Research & Development, LLC $9,404.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418853
Principal investigator 1 Janssen Research & Development, LLC $250.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418870
Principal investigator 1 Janssen Research & Development, LLC $520.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418939
Principal investigator 1 Janssen Research & Development, LLC $520.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418944
Principal investigator 1 Janssen Research & Development, LLC $15,744.00 07/24/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419003
Principal investigator 1 Eisai Inc. $8,554.50 07/21/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557429
Principal investigator 1 GlaxoSmithKline, LLC. $21,595.95 07/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145206
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $118,027.19 07/14/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235999063
Principal investigator 1 Eisai Inc. $18,110.70 07/07/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557427
Principal investigator 1 Janssen Research & Development, LLC $1,759.00 07/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418926
Principal investigator 1 Eisai Inc. $7,685.00 07/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557457
Principal investigator 1 Eisai Inc. $14,315.00 07/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557467
Principal investigator 1 Eisai Inc. $14,280.00 07/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557475
Principal investigator 1 Eisai Inc. $5,760.00 07/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557483
Principal investigator 1 Eisai Inc. $3,800.00 07/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557485
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $378.13 06/24/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235999067
Principal investigator 1 GlaxoSmithKline, LLC. $14,800.06 06/23/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145198
Principal investigator 1 Janssen Research & Development, LLC $18,818.00 06/23/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418847
Principal investigator 1 Janssen Research & Development, LLC $500.00 06/23/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419064
Principal investigator 1 Novo Nordisk AS $2,329.02 06/23/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214102391
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,381.00 06/18/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235999057
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145220
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/18/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149353
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135886
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135967
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138224
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148497
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149348
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179639
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180944
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 06/17/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184625
Principal investigator 1 GlaxoSmithKline, LLC. $5,805.00 06/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129378
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 06/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184634
Principal investigator 1 Eisai Inc. $7,675.00 06/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557469
Principal investigator 1 Eisai Inc. $19,855.00 06/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557473
Principal investigator 1 GlaxoSmithKline, LLC. $675.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129392
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135986
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142495
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142522
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146351
Principal investigator 1 GlaxoSmithKline, LLC. $1,350.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148484
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179659
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/30/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184617
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148501
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149357
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192176833
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179647
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179655
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 05/26/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180934
Principal investigator 1 Novo Nordisk AS $779.76 05/21/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214102505
Principal investigator 1 Janssen Research & Development, LLC $2,250.00 05/19/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418956
Principal investigator 1 GlaxoSmithKline, LLC. $12,638.70 05/13/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192142534
Principal investigator 1 Janssen Research & Development, LLC $2,080.00 05/09/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419022
Principal investigator 1 Janssen Research & Development, LLC $2,175.00 05/09/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419040
Principal investigator 1 Janssen Research & Development, LLC $16,065.00 05/05/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418991
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123199
Principal investigator 1 GlaxoSmithKline, LLC. $810.00 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127275
Principal investigator 1 GlaxoSmithKline, LLC. $797.85 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135903
Principal investigator 1 GlaxoSmithKline, LLC. $54.00 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138237
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 04/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192148505
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 04/21/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418864
Principal investigator 1 Janssen Research & Development, LLC $798.00 04/21/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418893
Principal investigator 1 Janssen Research & Development, LLC $2,508.00 04/21/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418995
Principal investigator 1 Janssen Research & Development, LLC $684.00 04/21/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419016
Principal investigator 1 Janssen Research & Development, LLC $13,490.00 04/21/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419029
Principal investigator 1 GlaxoSmithKline, LLC. $30,015.23 04/09/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146359
Principal investigator 1 Genentech, Inc. $794.14 04/08/2025 Non-covered Recipient Entity
AMC RESEARCH LLC MOHAMMAD REZA BOLOURI MD
PoM study of Brain Shuttle Gantenerumab in early AD No dispute reported 06/30/2026 1211572081
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129364
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135974
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138251
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138260
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192145215
Principal investigator 1 GlaxoSmithKline, LLC. $4,995.00 04/03/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179643
Principal investigator 1 Eisai Inc. $215.00 04/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557477
Principal investigator 1 Eisai Inc. $430.00 04/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557479
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 04/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149341
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 04/01/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192184630
Principal investigator 1 Janssen Research & Development, LLC $3,414.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418836
Principal investigator 1 Janssen Research & Development, LLC $250.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418919
Principal investigator 1 Janssen Research & Development, LLC $9,900.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418932
Principal investigator 1 Janssen Research & Development, LLC $1,660.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418962
Principal investigator 1 Janssen Research & Development, LLC $224,910.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418973
Principal investigator 1 Janssen Research & Development, LLC $500.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419054
Principal investigator 1 Janssen Research & Development, LLC $25,860.00 03/31/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419070
Principal investigator 1 Novo Nordisk AS $981.18 03/28/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214103629
Principal investigator 1 GlaxoSmithKline, LLC. $21,089.71 03/21/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140749
Principal investigator 1 Eisai Inc. $54,127.80 03/18/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557425
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192129385
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192135848
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138245
Principal investigator 1 GlaxoSmithKline, LLC. $4,995.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192140708
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146371
Principal investigator 1 GlaxoSmithKline, LLC. $40.50 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149336
Principal investigator 1 GlaxoSmithKline, LLC. $5,805.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149345
Principal investigator 1 GlaxoSmithKline, LLC. $202.50 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180949
Principal investigator 1 GlaxoSmithKline, LLC. $135.00 03/06/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180953
Principal investigator 1 Eisai Inc. $5,290.00 03/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557461
Principal investigator 1 Eisai Inc. $7,745.00 03/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557471
Principal investigator 1 GlaxoSmithKline, LLC. $405.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123180
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192123211
Principal investigator 1 GlaxoSmithKline, LLC. $5,805.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192146368
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149361
Principal investigator 1 GlaxoSmithKline, LLC. $1,080.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192149365
Principal investigator 1 GlaxoSmithKline, LLC. $60.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192179651
Principal investigator 1 GlaxoSmithKline, LLC. $540.00 02/25/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192180938
Principal investigator 1 GlaxoSmithKline, LLC. $27,837.68 02/24/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192138230
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $458,902.87 02/11/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999061
Principal investigator 1 Eli Lilly and Company $79,916.00 02/10/2025 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876553
Principal investigator 1 Janssen Research & Development, LLC $82,620.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418858
Principal investigator 1 Janssen Research & Development, LLC $13,770.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418907
Principal investigator 1 Janssen Research & Development, LLC $3,204.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418969
Principal investigator 1 Janssen Research & Development, LLC $2,964.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175418979
Principal investigator 1 Janssen Research & Development, LLC $684.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419035
Principal investigator 1 Janssen Research & Development, LLC $1,596.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419047
Principal investigator 1 Janssen Research & Development, LLC $114,750.00 02/07/2025 Non-covered Recipient Entity
AMC RESEARCH
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease No dispute reported 06/30/2026 1175419060
Principal investigator 1 Eisai Inc. $6,000.00 02/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557481
Principal investigator 1 Eli Lilly and Company $7,693.83 01/31/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876551
Principal investigator 1 Novo Nordisk AS $5,383.80 01/31/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER FLOURISH RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1214103455
Principal investigator 1 Biogen, Inc. $21,799.00 01/28/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1236947322
Principal investigator 1 GlaxoSmithKline, LLC. $25,631.10 01/28/2025 Non-covered Recipient Entity
CLINICAL SITE PARTNERS LLC
A PHASE 2, PARALLEL GROUP, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE No dispute reported 06/30/2026 1192127251
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,470.70 01/27/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999065
Principal investigator 1 Eli Lilly and Company $4,055.55 01/27/2025 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187874437
Principal investigator 1 Eli Lilly and Company $375.00 01/27/2025 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187876225
Principal investigator 1 Eli Lilly and Company $793,691.00 01/22/2025 Non-covered Recipient Entity
FLOURISH RESEARCH ACQUISITION LLC
A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187881190
Principal investigator 1 Eli Lilly and Company $28,407.00 01/21/2025 Non-covered Recipient Entity
ALZHEIMER'S MEMORY CENTER
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187876227
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61,871.40 01/03/2025 Non-covered Recipient Entity
Alzheimers Memory Center Flourish Research
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235999055
Principal investigator 1 Eisai Inc. $9,255.00 01/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557459
Principal investigator 1 Eisai Inc. $18,965.00 01/01/2025 Non-covered Recipient Entity
AMC Research LLC
A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) No dispute reported 06/30/2026 1244557463